Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch single-center cohort study

Authors

  • Johanna C. Wiersum-Osselton,

    Corresponding author
    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author
  • Suzanna M. van Walraven,

    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author
  • Ivan Bank,

    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author
  • A. Mariëtte Lenselink,

    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author
  • Willem E. Fibbe,

    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author
  • Johanna G. van der Bom,

    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author
  • Anneke Brand

    1. From the Donor Services Unit, Sanquin Blood Supply, Rotterdam, The Netherlands; the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands; and Europdonor Foundation; Sanquin–LUMC Jon J. van Rood Centre for Clinical Transfusion Research; and the Departments of Immunohematology and Blood Transfusion, and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
    Search for more papers by this author

Johanna C. Wiersum-Osselton, Sanquin Blood Supply, Wijtemaweg 10, Postbus 23370, 3001 KJ Rotterdam, the Netherlands; e-mail J.Wiersum@sanquin.nl.

Abstract

BACKGROUND: Relatives donating peripheral blood stem cells (PBSCs) may be accepted for donation on less strict criteria than unrelated donors. We evaluated the occurrence of adverse events during procedure and follow-up, with a special focus on donors who would have been deferred as unrelated donors.

STUDY DESIGN AND METHODS: All 268 related PBSC donors at our center (1996-2006) were included. Data were retrospectively collected from medical reports and standard follow-up. Health questionnaires were sent from 2007. Medical outcomes of donors, deferrable or eligible according to international criteria for unrelated donation, were compared.

RESULTS: Forty donors (15%) would have been deferred for unrelated donation. Short-term adverse events occurred in 2% of procedures. Questionnaires were returned by 162 (60%) donors on average 7.5 years after donation, bringing total person-years of follow-up to 1278 (177 in deferrable donors). Nine malignancies and 14 cardiovascular events were reported. The incidence rate of cardiovascular events in eligible donors was 6.5 (95% confidence interval [CI], 2.5-12.3) per 1000 person-years compared to 44.9 (95% CI, 17.4-85.2) in deferrable donors; incidence rates of malignancies were 4.6 (1.4-9.6) and 24.0 (6.0-53.9) per 1000 person-years, respectively, in eligible and deferrable donors. All incidence rates were within the range of age- and sex-matched general population. No autoimmune disorders were reported.

CONCLUSION: In both the eligible and the deferrable related donors treated with granulocyte–colony-stimulating factor there are few short-term and long-term problems. The occurrence of post-PBSC cardiovascular events and malignant disease in related donors appears to be within the range of the general population.

Ancillary